{"id":"triple-antithrombotic-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Major bleeding"},{"rate":null,"effect":"Minor bleeding"},{"rate":null,"effect":"Gastrointestinal hemorrhage"},{"rate":null,"effect":"Intracranial hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen typically combines an anticoagulant (such as warfarin or a direct oral anticoagulant) with dual antiplatelet therapy (aspirin and a P2Y12 inhibitor like clopidogrel). The combination targets different steps in the coagulation cascade and platelet aggregation, providing enhanced thrombotic protection in high-risk cardiovascular conditions. However, this approach significantly increases bleeding risk and is used selectively in specific clinical scenarios.","oneSentence":"Triple antithrombotic therapy combines three anticoagulant or antiplatelet agents to prevent blood clot formation through multiple complementary pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:43.503Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with concurrent indication for anticoagulation"},{"name":"Atrial fibrillation with acute coronary syndrome or recent percutaneous coronary intervention"}]},"trialDetails":[{"nctId":"NCT04347187","phase":"","title":"REGistry of Long-term AnTithrombotic TherApy-2","status":"RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2015-01-15","conditions":"Atrial Fibrillation","enrollment":2000},{"nctId":"NCT04347200","phase":"","title":"REGistry of Long-term AnTithrombotic TherApy-1","status":"RECRUITING","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2015-01-15","conditions":"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Peripheral Artery Disease","enrollment":2000},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT05638867","phase":"PHASE4","title":"NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-25","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome","enrollment":3944},{"nctId":"NCT04436978","phase":"PHASE4","title":"What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-01-11","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation","enrollment":2000},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT03234114","phase":"PHASE4","title":"Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-03","conditions":"Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)","enrollment":3746},{"nctId":"NCT02206815","phase":"PHASE4","title":"Safety of \"Ticagrelor+ Warfarin\"in Comparison With \"Clopidogrel+Aspirin+Warfarin\"","status":"COMPLETED","sponsor":"Genshan Ma","startDate":"2014-09-19","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":296},{"nctId":"NCT04695106","phase":"PHASE4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2021-10-25","conditions":"Atrial Fibrillation, Antithrombotic Therapy, Acute Coronary Syndrome","enrollment":2230},{"nctId":"NCT03889574","phase":"","title":"Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2019-02-26","conditions":"Cardiac Disease","enrollment":84},{"nctId":"NCT04291287","phase":"","title":"Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)","status":"UNKNOWN","sponsor":"Scientific Institute San Raffaele","startDate":"2020-01-25","conditions":"Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding","enrollment":1500},{"nctId":"NCT02606552","phase":"PHASE4","title":"Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease","status":"TERMINATED","sponsor":"Yonsei University","startDate":"2016-07-20","conditions":"Atrial Fibrillation, Coronary Artery Disease","enrollment":9},{"nctId":"NCT02164864","phase":"PHASE3","title":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-22","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2725},{"nctId":"NCT03203980","phase":"","title":"Bleeding Events After Triple Antithrombotic Therapy Initiation.","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2017-07-15","conditions":"Bleeding","enrollment":200},{"nctId":"NCT00776633","phase":"PHASE4","title":"Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2008-09","conditions":"Coronary Artery Disease, Atrial Fibrillation","enrollment":614},{"nctId":"NCT02334254","phase":"PHASE4","title":"Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2013-08","conditions":"Atrial Fibrillation","enrollment":420},{"nctId":"NCT01812200","phase":"PHASE4","title":"Antithrombotic Triple Therapy in Humans","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-10","conditions":"Atrial Fibrillation, Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT00769938","phase":"PHASE4","title":"WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)","status":"COMPLETED","sponsor":"R&D Cardiologie","startDate":"2008-12","conditions":"Anticoagulants, Platelet Aggregation Inhibitors, Stents","enrollment":573}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":351,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAT"],"phase":"marketed","status":"active","brandName":"Triple antithrombotic therapy","genericName":"Triple antithrombotic therapy","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triple antithrombotic therapy combines three anticoagulant or antiplatelet agents to prevent blood clot formation through multiple complementary pathways. Used for Acute coronary syndrome with concurrent indication for anticoagulation, Atrial fibrillation with acute coronary syndrome or recent percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}